Financhill
Sell
39

BIIB Quote, Financials, Valuation and Earnings

Last price:
$137.09
Seasonality move :
-2.65%
Day range:
$136.52 - $138.94
52-week range:
$128.51 - $238.00
Dividend yield:
0%
P/E ratio:
12.21x
P/S ratio:
2.06x
P/B ratio:
1.20x
Volume:
1.5M
Avg. volume:
1.5M
1-year change:
-37.47%
Market cap:
$20B
Revenue:
$9.7B
EPS (TTM):
$11.19

Analysts' Opinion

  • Consensus Rating
    Biogen has received a consensus rating of Hold. The company's average rating is a Hold based on 13 Buy ratings, 17 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $201.38, Biogen has an estimated upside of 47.34% from its current price of $137.08.
  • Price Target Downside
    According to analysts, the lowest downside price target is $135.00 representing 1.23% downside risk from its current price of $137.08.

Fair Value

  • According to the consensus of 30 analysts, Biogen has 47.34% upside to fair value with a price target of $201.38 per share.

BIIB vs. S&P 500

  • Over the past 5 trading days, Biogen has underperformed the S&P 500 by -2.42% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Biogen does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Biogen has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Biogen reported revenues of $2.5B.

Earnings Growth

  • Biogen has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Biogen reported earnings per share of $1.83.
Enterprise value:
23.9B
EV / Invested capital:
1.04x
Price / LTM sales:
2.06x
EV / EBIT:
11.10x
EV / Revenue:
2.47x
PEG ratio (5yr expected):
0.30x
EV / Free cash flow:
9.51x
Price / Operating cash flow:
7.93x
Enterprise value / EBITDA:
8.46x
Gross Profit (TTM):
$7.4B
Return On Assets:
5.98%
Net Income Margin (TTM):
16.87%
Return On Equity:
10.33%
Return On Invested Capital:
7.33%
Operating Margin:
18.36%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $10.2B $9.8B $9.7B $2.4B $2.5B
Gross Profit $7.9B $7.3B $7.4B $1.8B $1.9B
Operating Income $2.9B $1.8B $2.2B $457.7M $450.6M
EBITDA $4.4B $2B $2.8B $503.2M $535.5M
Diluted EPS $20.93 $7.98 $11.19 $1.71 $1.83
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $6.9B $7.9B $9.8B $6.9B $7.5B
Total Assets $24.6B $23.9B $24.6B $26.8B $28B
Current Liabilities $3.7B $4.3B $3.3B $3.4B $5.5B
Total Liabilities $13.9B $12.9B $11.2B $12B $11.3B
Total Equity $10.7B $11B $13.4B $14.8B $16.7B
Total Debt $7.4B $7.3B $6.3B $6.9B $6.3B
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations $1.4B $1.5B $2.9B $12.5M $760.9M
Cash From Investing $1.6B -$4.1B -$799.2M -$652.3M -$18.6M
Cash From Financing -$1.7B $149.3M -$683.5M -$646.1M $7.9M
Free Cash Flow $1.1B $1.2B $2.5B -$52.7M $694.6M
BIIB
Sector
Market Cap
$20B
$44.2M
Price % of 52-Week High
57.43%
48.19%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-37.61%
-35.43%
Beta (5-Year)
-0.082
0.747
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $137.68
200-day SMA
Sell
Level $188.79
Bollinger Bands (100)
Sell
Level 143.42 - 178.94
Chaikin Money Flow
Buy
Level 64M
20-day SMA
Sell
Level $141.71
Relative Strength Index (RSI14)
Sell
Level 39.57
ADX Line
Sell
Level 23.59
Williams %R
Neutral
Level -57.2952
50-day SMA
Sell
Level $146.40
MACD (12, 26)
Sell
Level -3.07
25-day Aroon Oscillator
Sell
Level -80
On Balance Volume
Neutral
Level 291.9M

Financial Scores

Hold
Altman Z-Score (Annual)
Level (2.8221)
Buy
CA Score (Annual)
Level (0.3672)
Buy
Beneish M-Score (Annual)
Level (-2.8061)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-2.0199)
Buy
Piotroski F Score (Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Stock Forecast FAQ

In the current month, BIIB has received 13 Buy ratings 17 Hold ratings, and 0 Sell ratings. The BIIB average analyst price target in the past 3 months is $201.38.

  • Where Will Biogen Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Biogen share price will rise to $201.38 per share over the next 12 months.

  • What Do Analysts Say About Biogen?

    Analysts are divided on their view about Biogen share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Biogen is a Sell and believe this share price will drop from its current level to $135.00.

  • What Is Biogen's Price Target?

    The price target for Biogen over the next 1-year time period is forecast to be $201.38 according to 30 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 17 analysts rate the stock a Hold.

  • Is BIIB A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Biogen is a Hold. 17 of 30 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of BIIB?

    You can purchase shares of Biogen via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Biogen shares.

  • What Is The Biogen Share Price Today?

    Biogen was last trading at $137.09 per share. This represents the most recent stock quote for Biogen. Yesterday, Biogen closed at $137.08 per share.

  • How To Buy Biogen Stock Online?

    In order to purchase Biogen stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is SoFi Worth?
What Is SoFi Worth?

Since SoFi’s CEO began snapping up shares of the student…

Is CVX a Buy, Sell or Hold?
Is CVX a Buy, Sell or Hold?

Energy giant Chevron Corporation (NYSE:CVX) has long been a pure-play…

What Will NVIDIA Stock Be Worth in 2030?
What Will NVIDIA Stock Be Worth in 2030?

NVIDIA (NASDAQ:NVDA) has been by far one of the best…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
60
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Sell
17
CE alert for Feb 21

Celanese [CE] is down 4.21% over the past day.

Sell
22
GLBE alert for Feb 20

Global E Online [GLBE] is down 8.41% over the past day.

Buy
72
HIMS alert for Feb 20

Hims & Hers Health [HIMS] is down 3.39% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock